A detailed history of Rock Point Advisors, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Rock Point Advisors, LLC holds 1,840 shares of BIIB stock, worth $290,738. This represents 0.1% of its overall portfolio holdings.

Number of Shares
1,840
Previous 1,840 -0.0%
Holding current value
$290,738
Previous $426,000 16.43%
% of portfolio
0.1%
Previous 0.13%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

BUY
$253.3 - $285.89 $466,072 - $526,037
1,840 New
1,840 $472,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $22.8B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Rock Point Advisors, LLC Portfolio

Follow Rock Point Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Point Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rock Point Advisors, LLC with notifications on news.